Monday, February 10, 2014
FDA and state governments are finalizing ground rules
that will determine whether the U.S. marketplace for biosimilars will look more
like specialty pharmaceuticals, or evolve into a model that has more in common
with the generic drug marketplace.
For years, innovator biologics
manufacturers battled companies that wanted to create an American biosimilars
industry, skirmishing over the scientific and legal standards for demonstrating